• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5070974)   Today's Articles (61)
For: Srinivasan R, Iliopoulos O, Beckermann KE, Narayan V, Maughan BL, Oudard S, Else T, Maranchie JK, Iversen AB, Cornell J, Perini RF, Liu Y, Linehan WM, Jonasch E. Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study. Lancet Oncol 2025;26:571-582. [PMID: 40228516 PMCID: PMC12050119 DOI: 10.1016/s1470-2045(25)00099-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2024] [Revised: 02/06/2025] [Accepted: 02/19/2025] [Indexed: 04/16/2025]
Number Cited by Other Article(s)
1
Sidaway P. Durable responses to belzutifan in patients with VHL disease. Nat Rev Clin Oncol 2025;22:382. [PMID: 40281323 DOI: 10.1038/s41571-025-01023-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2025]
2
Ciccarese C, Iacovelli R, Tortora G. Belzutifan in von Hippel-Lindau disease. Lancet Oncol 2025;26:531-533. [PMID: 40228515 DOI: 10.1016/s1470-2045(25)00153-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2025] [Revised: 03/12/2025] [Accepted: 03/12/2025] [Indexed: 04/16/2025]
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA